Literature DB >> 20186008

Analytical performance of a qRT-PCR assay to detect guanylyl cyclase C in FFPE lymph nodes of patients with colon cancer.

Martin Beaulieu1, Marie Desaulniers, Nicolas Bertrand, Réna G Deschesnes, Guillaume Beaudry, Geneviève Garon, Jean-François Haince, Michel Houde, Timothy J Holzer.   

Abstract

Up to 30% of patients with stage II (pN0) colon cancer develop recurrences, suggesting that the presence of lymph node (LN) metastases escaped detection at histopathologic staging. A simple way to overcome this limitation and to improve staging accuracy is to use reverse transcription-polymerase chain reaction (RT-PCR) to examine a larger fraction or an entire specimen. The Guanylyl cyclase C (GCC) gene is uniquely expressed in apical cells of the gastrointestinal tract. Its expression in colon cancer cells and metastases is conserved. Therefore, detection of GCC mRNA in LNs has been shown to be indicative of the presence of colon cancer metastases. As the current processing of LNs involves formalin fixation and paraffin embedding, we developed a method for extracting RNA from formalin-fixed paraffin-embedded LN specimens and detecting GCC mRNA by quantitative RT-PCR. The assay has a dynamic range of 5 logs, an average amplification efficiency of 98.4% (95% confidence interval, 96.6-100.3), a reaction linearity of 0.998 (95% confidence interval, 0.997-0.999), and also intraplate and interplate CVs of <1% and <5%, respectively. The test specificity was 98% with LNs collected from patients affected by conditions other than colon cancer (n=380). Sensitivity was 97% for patients with stage III colon cancer (n=34), whereas 35% of patients with stages I and II disease (n=51) had at least 1 GCC mRNA-positive LN. The high specificity of GCC mRNA suggests that routine utilization of the quantitative RT-PCR test has the potential to improve the detection of colon cancer metastases in LNs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20186008     DOI: 10.1097/PDM.0b013e3181ad5ac3

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  11 in total

1.  Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.

Authors:  Terry Hyslop; David S Weinberg; Stephanie Schulz; Alan Barkun; Scott A Waldman
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

Review 2.  GUCY2C molecular staging personalizes colorectal cancer patient management.

Authors:  Jian P Gong; Stephanie Schulz; Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

Review 3.  Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.

Authors:  Lokesh Agrawal; Kelly B Engel; Sarah R Greytak; Helen M Moore
Journal:  Semin Cancer Biol       Date:  2017-12-16       Impact factor: 15.707

Review 4.  Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.

Authors:  Allison A Aka; Jeff A Rappaport; Amanda M Pattison; Takami Sato; Adam E Snook; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2017-04-10       Impact factor: 5.045

5.  Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer.

Authors:  Terry Hyslop; David S Weinberg; Stephanie Schulz; Alan Barkun; Scott A Waldman
Journal:  J Surg Oncol       Date:  2012-01-17       Impact factor: 3.454

Review 6.  Guanylyl cyclase C as a biomarker in colorectal cancer.

Authors:  Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

7.  GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.

Authors:  Amanda N Lisby; John C Flickinger; Babar Bashir; Megan Weindorfer; Sanjna Shelukar; Madison Crutcher; Adam E Snook; Scott A Waldman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-02-02

Review 8.  Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.

Authors:  Ariana A Entezari; Adam E Snook; Scott A Waldman
Journal:  Expert Opin Ther Targets       Date:  2021-06-15       Impact factor: 6.797

9.  Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.

Authors:  John C Flickinger; Jeffrey A Rappaport; Joshua R Barton; Trevor R Baybutt; Amanda M Pattison; Adam E Snook; Scott A Waldman
Journal:  Biomark Med       Date:  2021-01-20       Impact factor: 2.851

10.  Molecular staging of node negative patients with colorectal cancer.

Authors:  Terry Hyslop; Scott A Waldman
Journal:  J Cancer       Date:  2013-03-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.